The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the ...
ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology ...
Daiichi Sankyo has emerged victorious in appeals court, flipping a prior multimillion-dollar patent verdict on its head and ...
Daiichi Sankyo continues to advance its pipeline, offering positive catalysts over the next year. Click here to read why ...
More recently, the FDA posted two two letters: one backdated for September 9, regarding GSK’s HIV medication Apretude and one ...
Daiichi Sankyo’s Dr Michael Zaiac discusses how AI, biomarkers and targeted therapies are shaping oncology’s future.
A U.S. appeals court on Tuesday overturned a nearly $42 million jury verdict won by Pfizer's Seagen against Japanese rival ...
After a string of new approvals, Daiichi Sankyo is boosting sales projection for AstraZeneca-partnered star cancer drug Enhertu. Daiichi now expects Enhertu could reach sales of 195.2 billion Japanese ...
On December 2, the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) reversed a decision from the U.S.
Khaleej Times on MSN
US FDA approves AstraZeneca, Daiichi's breast cancer drug as first-line treatment
The US Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback